Microbot Medical, Inc. Common Stock (MBOT) is a publicly traded Healthcare sector company. As of October 20, 2026, MBOT trades at $1.00 with a market cap of $63.81M and a P/E ratio of -3.74. MBOT moved +3.81% today. Year to date, MBOT is -54.84%; over the trailing twelve months it is -65.48%. Its 52-week range spans $0.93 to $4.67. Analyst consensus is strong buy with an average price target of $6.33. Rallies surfaces MBOT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Microbot Medical signs three-year exclusive distribution deal with Medtechnica in Israel for LIBERTY system: Microbot Medical signed a three-year exclusive deal for Medtechnica to market and sell its LIBERTY endovascular robotic system in Israel. The system received Israeli Ministry of Health AMAR clearance and was registered in May 2026; initial orders are expected in Q4 2026.
| Metric | Value |
|---|---|
| Price | $1.00 |
| Market Cap | $63.81M |
| P/E Ratio | -3.74 |
| EPS | $-0.29 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.67 |
| 52-Week Low | $0.93 |
| Volume | 282.11K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-13.14M |
| Gross Margin | 0.00% |
3 analysts cover MBOT: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.33.